Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity
← catalyst calendarNCT07523711 · readout in 91 d
Sponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
49actual
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-04-09 | actual | When the study began enrolling |
| Primary completion | 2026-11-18 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-11-18 | estimated | The whole study's end, after follow-up |
| First posted | 2026-04-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Overweight
- Obesity
Interventions
- Drug: COC
- Drug: Maridebart Cafraglutide — also filed as AMG 133
Primary outcomes
what the primary-completion date above is the date OFMaximum Observed Concentration (Cmax) of COC
measured Day 1 up to Day 89
Area Under the Concentration-time Curve (AUC) from Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of COC
measured Day 1 up to Day 89
AUC from Time Zero Extrapolated to Infinity (AUCinf) of COC
measured Day 1 up to Day 89
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed